Creyos, a digital cognitive health assessment company, has published peer-reviewed research in the Journal of Alzheimer's Disease validating its two-task digital screener for dementia detection. The study, conducted by Western University researchers, found the screener achieved 100% sensitivity and 86% specificity in detecting Alzheimer's disease in approximately six minutes. The screener uses two tasks from Creyos's platform—a visuospatial working memory task and an attention task—analysed through machine learning models trained on data from over 20 million task completions. Researchers validated the system against datasets comprising 9,350 individuals aged 21 to 97. The screener outperformed the traditional Mini-Mental State Examination, correctly identifying one Alzheimer's patient who scored above MMSE's impairment threshold. Results remained consistent across gender, education level and study populations, with outcomes specifically identifying dementia-related impairment rather than other health conditions.

AI, digital adoption, and wearable tech: key insights from NPA 2026. Table Of Contents Creyos was a proud attendee of the 2026 NPA Psychopharmacology Update in Las Vegas, Nevada, from February 11 to 14, 2026. While this year's conference could be attended either online or in person, its team was too excited to attend from home and made the trek to sunny Nevada for the one-of-a-kind four-day event. The NPA Psychopharmacology Update is one of the largest psychopharmacology conferences in the US and has hosted over 2,000 attendees from all 50 states in addition to attendees from around the world. This conference presents a unique opportunity to engage in four days of impactful discussions and insightful lectures from internationally esteemed mental healthcare professionals. Those in attendance had the privilege of exploring new approaches to treatments and listening to enlightened debates on the latest ethics and legal implications of evolving technology - all through dynamic presentations. | Key Takeaways: * AI is continuing to climb in the healthcare industry * Digital adoption requires both legal and ethical considerations * ADHD treatments are evolving * Wearable tech might have a future for depression treatment | The event was the perfect opportunity to discuss the future of mental health care with psychiatrists, nurse practitioners, physician assistants, primary care physicians, and other mental health professionals. NPA 2026 offered all of its various exhibitors and sponsors a can't-miss opportunity to connect with key decision-makers and industry leaders to explore cutting-edge solutions in mental healthcare treatment. It is no wonder that the conference's audience was so engaged, as this opportunity to forge meaningful relationships and work towards a brighter future was like none other. Some Key Event Highlights In addition to meeting with a variety of incredibly well-informed professionals from across the mental health field, the Creyos team also attended an array of incredibly insightful talks and roundtables throughout the week. A few of its favorite discussions from this year's lineup included: AI, Almighty and Inevitable: The use of AI in Medical Practice This top-of-mind topic was tackled by Dr. Andrew Nanton, MD, on February 11. AI is continuing its climb in healthcare, and as adoption grows, more and more providers are exploring how AI can benefit their practices and their patients. The Cyber-Boundaries of Digital Professionalism: Avoiding Legal & Ethical Dangers Digital technology has the power to transform, but it can also open the door to potential legal and ethical issues. Dr. James Knoll, MD, hosted this fantastic talk on February 11 about how providers can ensure they are protected legally and approach integration with the best possible intentions as digital technology becomes an increasingly important part of running a modern medical practice. ADHD: Treatment Updates Dr. James McGough, MD, hosted this fantastic talk on February 13 about how ADHD treatments are evolving. For years, providers have noted that ADHD cases are on the rise as awareness about the condition grows. But alongside this growing demand is an evolving treatment landscape. As awareness of ADHD grows and changes with new technology and research, so too do treatment recommendations. Use of Wearable Technologies in the Treatment of Depression Hosted by Paola Pedrelli, MD, on February 14, this discussion centered around the adoption of wearable technologies for the treatment of depression. Creyos is always keen to learn more about new technologies in the medical world and explore the latest ways in which patients with potentially critical cognitive conditions can be aided through advancements in tech. If you want to learn more about some of the critical insights Creyos heard at the 2026 NPA Psychopharmacology Update in Las Vegas, reach out and connect with one of its team members. The Future of Mental Health Care With so many esteemed professionals focused on advancing treatments and so carefully considering the potential impact of any changes they make, NPA 2026 made it clear that the future of mental healthcare is in good hands - and that future looks bright. Advancing technology has the potential to revolutionize the way Creyos approach mental healthcare assessment and treatment monitoring. In particular, digital cognitive testing like that from Creyos gives providers objective insights that make diagnostic processes easier and more streamlined. This leads to quicker, more confident clinical decision-making and faster access to treatment for patients. This testing also allows for longitudinal testing, making it ideal for treatment monitoring and ongoing assessment. In clinical practice, assessments can provide mental healthcare professionals with objective measurements to better understand how conditions like ADHD, depression, anxiety, or other mental health conditions are impacting their cognition. Importantly, these tests are also made with privacy in mind and are completely HIPAA compliant so that providers can assess patients knowing their private healthcare information is safe. If you're looking to advance your mental health assessment with digital cognitive testing, reach out to learn more about how comprehensive digital cognitive assessments can help bring your practice into the future. Measure the Cognitive Impact of Anxiety Backed by over 30 years of research, Creyos is here to help you confidently measure cognitive markers of anxiety to deliver better patient outcomes, faster. Talk to an Expert Join thousands of healthcare professionals who receive a monthly update on the latest research and news in brain health.